Internal Reference Number: FOI_8213
Date Request Received: 18/10/2024 00:00:00
Date Request Replied To: 23/10/2024 00:00:00
This response was sent via: By Email
Request Summary: High-cost drugs in Ophthalmology
Request Category: Researcher
| Question Number 1: For the 4 months from May to August 2024, how many unique patients received the following intra-vitreal treatments for any eye condition: Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab - Lucentis Ranibizumab – Ongavia Ranibizumab - Ximluci | |
| Answer To Question 1: Aflibercept 580 Bevacizumab 10 Brolucizumab 0 Dexamethasone 13 Faricimab 325 Ranibizumab - Lucentis 0 Ranibizumab – Ongavia 0 Ranibizumab – Ximluci 0 | |
| Question Number 2: For the patients above, how many were new to intra-vitreal treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments. Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab - Lucentis Ranibizumab – Ongavia Ranibizumab - Ximluci | |
| Answer To Question 2: Aflibercept 64 Bevacizumab 6 Brolucizumab 0 Dexamethasone <5 Faricimab 38 Ranibizumab - Lucentis 0 Ranibizumab – Ongavia 0 Ranibizumab - Ximluci 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
